Randomized trials in patients with advanced non-small-cell lung cancer (NSCLC) have demonstrated that the combination of vinorelbine (Navelbine) and cisplatin
Mark A. O'Rourke, MD
Advertisement
Articles by Mark A. O'Rourke, MD
Two large-scale, randomized, phase III trials have offered new information on the response rates, survival benefits, and safety profile of vinorelbine (Navelbine) in non-small-cell lung cancer (NSCLC). In a multicenter, European trial, the response rate was significantly higher with vinorelbine/cisplatin (Platinol) than with vindesine (Eldisine)/cisplatin (P < .02) or vinorelbine alone (P < .001).
Advertisement
Latest Updated Articles
- Vinorelbine and Carboplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer
Published: October 2nd 1997 | Updated:
- Historical Review of Trials With Vinorelbine in Non-Small-Cell Lung Cancer
Published: October 2nd 1997 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
2
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
3
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
4
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
5
